Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study

GlobeNewswire April 1, 2019

Algernon Taps Expert Clinician for Advisory Board

Stockhouse Editorial March 21, 2019

Algernon Pharmaceuticals Appoints Leading Liver Disease Expert Dr. Arun Sanyal to Its Medical and Scientific Advisory Board

GlobeNewswire March 21, 2019

Algernon Retains Renmark Financial Communications

GlobeNewswire March 12, 2019

Algernon Pharma Expands Research into Global Disease

Stockhouse Editorial February 25, 2019

Algernon Pharmaceuticals Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis

GlobeNewswire February 25, 2019

Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN

Stockhouse.com February 19, 2019

Breathtec to become Algernon Pharmaceuticals

Stockhouse Editorial February 15, 2019

Breathtec Announces Name Change to Algernon Pharmaceuticals

Stockhouse.com February 14, 2019

Nash Pharmaceuticals to Present Data on Its Inflammatory Bowel Disease Research Program at The Digestive Disease Week Annual Conference

GlobeNewswire February 13, 2019

Solving One of the Next Epidemic-Level Chronic Diseases

Danny Deadlock February 11, 2019

Nash Pharma to Present Fatty Liver Disease Data in London

Stockhouse Editorial February 1, 2019

Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK

GlobeNewswire January 31, 2019

Nash Pharma Study Reports Reduction in Fatty Liver Disease

Stockhouse Editorial January 21, 2019

Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease

GlobeNewswire January 21, 2019

New Kidney Disease Treatment Discovered by Nash Pharma

Stockhouse Editorial January 14, 2019

Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease as well as 2 Additional Lead Targets

GlobeNewswire January 14, 2019

Shareholder Press Release

GlobeNewswire January 10, 2019

Nash Pharmaceuticals: Three-Part Investor Series

Stockhouse Editorial December 5, 2018

Nash Pharmaceuticals 3: Strong Bet for Multi-Bagger Payoff

Jeff Nielson December 4, 2018